Investment Thesis
Revenue collapse of 31.8% YoY combined with operating losses, negative operating cash flow, and free cash flow of -$592K indicate severe operational distress. Gross margin of 16.7% is critically low for the pharmaceutical sector (typically 70-80%), suggesting fundamental competitive or pricing challenges. Company is burning cash and lacks clear path to profitability without dramatic turnaround.
Strengths
- Strong liquidity position with current ratio of 3.74x and quick ratio of 3.43x
- Conservative leverage with debt-to-equity ratio of only 0.23x limits financial risk
- Cash balance of $9.6M provides near-term operational runway
Risks
- Catastrophic 31.8% revenue decline YoY indicates loss of market share or product demand collapse
- Negative operating cash flow (-$167K) and free cash flow (-$592K) show company is not self-sustaining
- Gross margin of 16.7% is dangerously low for pharma; suggests structural cost/pricing dysfunction or product obsolescence
- Negative interest coverage ratio (-3.4x) means operations cannot support debt obligations
- Current cash burn rate will exhaust $9.6M reserve within 16+ months without operational improvement
Key Metrics to Watch
- Revenue stabilization and YoY growth recovery
- Gross margin improvement toward industry norms (70%+)
- Return to positive operating cash flow
- Cash runway and monthly burn rate depletion
- Operating income path to profitability
Financial Metrics
Revenue
17.3M
Net Income
-1.6M
EPS (Diluted)
$-0.04
Free Cash Flow
-592.0K
Total Assets
57.4M
Cash
9.6M
Profitability Ratios
Gross Margin
16.7%
Operating Margin
-8.5%
Net Margin
-9.3%
ROE
-4.5%
ROA
-2.8%
FCF Margin
-3.4%
Balance Sheet & Liquidity
Current Ratio
3.74x
Quick Ratio
3.43x
Debt/Equity
0.23x
Debt/Assets
37.6%
Interest Coverage
-3.43x
Long-term Debt
8.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T12:54:30.301341 |
Data as of: 2026-03-31 |
Powered by Claude AI